Key Highlights:
- Pfizer and GSK have amicably resolved their patent conflict, clearing the path for their RSV vaccines.
- Pfizer's stock has an average expected price target of $30.86, signaling potential upside for investors.
- GuruFocus analysis suggests Pfizer's fair value is projected to reach $28.65 within a year.
Pfizer Inc. (PFE) has successfully resolved a critical patent dispute with GSK concerning its RSV vaccine, Abrysvo. This legal battle, initiated by GSK's claims of patent infringement related to its Arexvy vaccine, has now been settled. The lawsuit will be dismissed with prejudice, ending the conflict that emerged after both vaccines gained FDA approval in 2023.
Wall Street's Outlook on Pfizer
Analysts have projected a positive outlook for Pfizer Inc. over the next year. According to estimates by 19 analysts, the average price target for Pfizer stands at $30.86, with forecasts ranging from a high of $41.43 to a low of $25.00. This average target suggests a potential upside of 27.07% from the current trading price of $24.29. For further insights into these estimates, visit the Pfizer Inc. (PFE, Financial) Forecast page.
The brokerage community maintains an optimistic stance on Pfizer's stock, with 23 firms assigning it an "Outperform" rating. This is reflected in the stock's average brokerage recommendation of 2.5 on a scale where 1 denotes a Strong Buy and 5 signals a Sell.
Intrinsic Value Assessment by GuruFocus
According to the GF Value calculation by GuruFocus, Pfizer's intrinsic value is estimated at $28.65 in the forthcoming year. This represents a projected upside of 17.95% from its current price point of $24.29. The GF Value metric is derived from historical trading multiples, business growth patterns, and future performance projections. More detailed data on this valuation can be accessed on the Pfizer Inc. (PFE, Financial) Summary page.
